Photo of Jennifer Veneris,  MD, PhD

Jennifer Veneris, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-5269


Jennifer_Veneris@dfci.harvard.edu

Jennifer Veneris, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Attending Physician, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

Jennifer Veneris, MD, PhD, is an Instructor in Medicine at Harvard Medical School and a Medical Oncologist in the gynecologic oncology program in Dana-Farber Cancer Institute’s Susan F. Smith Center for Women’s Cancers. Dr. Veneris joined the GYN program at DFCI in July 2018, where she is active in clinical and translational research in gynecologic malignancies, with interest in endocrine therapies and DNA damage repair in gynecologic malignancies.

Dr. Veneris received her undergraduate degree from Dartmouth College, Doctor of Medicine degree and Doctor of Philosophy in Cancer Biology at The University of Chicago, where she performed research on ovarian cancer metastatic colonization. She completed her Internal Medicine and Fellowship training in Hematology-Oncology at The University of Chicago Medicine in 2018, where she pursued research on the role of glucocorticoid receptor expression and function in chemotherapy resistance in gynecologic cancer.

Dr. Veneris is a recipient of awards and honors including a Conquer Cancer Foundation/American Society for Clinical Oncology Young Investigator Award.

Publications

Powered by Harvard Catalyst
  • Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol 2018; 146:153-160. PubMed
  • Tangen IL, Veneris JT, Halle MK, Werner HM, Trovik J, Akslen LA, Salvesen HB, Conzen SD, Fleming GF, Krakstad C. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecol Oncol 2017; 147:672-677. PubMed
  • Krishnan V, Stadick N, Clark R, Bainer R, Veneris JT, Khan S, Drew A, Rinker-Schaeffer C. Using MKK4's metastasis suppressor function to identify and dissect cancer cell-microenvironment interactions during metastatic colonization. Cancer Metastasis Rev 2017; 31:605-13. PubMed
  • Bainer RO, Veneris JT, Yamada SD, Montag A, Lingen MW, Gilad Y, Rinker-Schaeffer CW. Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization. Clin Exp Metastasis 2017; 29:397-408. PubMed